Medical Devices
Diabetes products lead adverse-event filings
Blood glucose meters and test strips made by the Johnson & Johnson subsidiary LifeScan accounted for the largest number of adverse-event reports that were filed without public disclosure in a U.S. Food and Drug Administration program that has since been closed down.
An initial review of data released June 21 by the FDA showed LifeScan filed 2.3 million secret adverse-event reports regarding its SureStep Flexx glucose meter and related diabetes products intended to be used in hospitals between 2006 and 2018. That was more than 20% of the entire data set. The previously undisclosed FDA data trove included nearly 6 million reports covering more than 100 different products made by dozens of different companies.
The second-highest total was for dental implants and supplies made by Nobel Biocare, a subsidiary of Washington-based conglomerate Danaher Corp. Federal law requires the makers of medical devices to file reports with the FDA in situations where the device caused or may have caused health problems in a patient, or when a device malfunctions in a way likely to happen again.
However, the FDA quietly gave out more than 100 exemptions since 1999, covering between seven events and 2.3 million events each, in situations where the agency said the problems were already well-known. The exemptions allowed manufacturers to file spreadsheets of events through a program known as Alternative Summary Reporting (ASR).
Regarding the devices generating the most reports, an FDA spokesman said in a statement to the Star Tribune: "Both of these products are commonly used medical devices, and therefore it is expected that reported events for those devices would represent a larger portion of the events than those for devices that are not commonly used."
The FDA in 2014 allowed Medtronic to file summaries of more than 1,000 reports of patient harm following the use of its controversial Infuse bone-growth product.
Although the filings were more than five years late, and included four patient deaths, the FDA decided the potential risks described in the reports were already known to the medical community by the time they were submitted.
joe Carlson